Evidence map›Paper›PMID 41703715›Full record

ReviewCancer biology & medicine2026

Applying microfluidic technology to interpret the tumor immune microenvironment and cancer immunotherapy.

Xuhong Chen, Dongxian Tan, Shuaiting Liu, Ruolin Luo, Yang Liu, Miaomiao Zhang, Siqi Li, Jing Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuhong ChenMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Dongxian TanMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Shuaiting LiuMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Ruolin LuoMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Yang LiuMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Miaomiao ZhangMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Siqi LiMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Jing XuMedical Research Center, Southern University of Science and Technology Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0002-2035-3482

Funding

Guangdong Basic and Applied Basic Research Foundation 2021A1515010115Guangdong Basic and Applied Basic Research Foundation 2022A1515012625Nanshan District Health System Technology Major Project NSZD2023056Nanshan District Health System Technology Major Project NSZD2024070National Natural Science Foundation of China 82371747Shenzhen Science and Technology Program JCYJ20210324103611030Shenzhen Science and Technology Program JCYJ20240813093903005Southern University of Science and Technology Hospital Foundation for High-level Talents 2021-012
6 · The paper itself

Abstract

In the past decade, cancer immunotherapy has emerged as a transformative treatment modality for diverse malignancies. Although impressive clinical efficacy has been demonstrated in some cancer patients, most patients respond poorly to immunotherapies. The complicated architecture and cellular composition of the tumor immune microenvironment (TIME) have substantial roles in the clinical outcomes of immunotherapies. Therefore, employing optimal

Indexed as

ImmunotherapyMicrofluidicsNeoplasmsTumor MicroenvironmentAnimalsHumanscancer immunologycell‒cell interactionsimmunotherapyMicrofluidic chiptumor immune microenvironment

Identifiers

PMID41703715
PMCPMC12980036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.